Loading...
12 nigella sativa COVID-19 controlled studies, 9 RCTs
69% improvement
for early treatment, RR
0.31
[0.12-0.77]
https://c19early.org/nsmeta.html
0
0.25
0.5
0.75
1
1.25
1.5
1.75
2+
HNS-COVID-PK
Ashraf (RCT)
82%
0.18 [0.04-0.80]
death
2/157
11/156
CT1
Improvement, RR [CI]
Treatment
Control
HNS-COVID-PK
Ashraf (RCT)
67%
0.33 [0.01-7.99]
death
0/107
1/103
CT1
HNS-COVID-PK
Ashraf (RCT)
79%
0.21 [0.05-0.92]
death
2/50
10/53
CT1
HNS-COVID-PK
Ashraf (RCT)
84%
0.16 [0.11-0.24]
no recov.
107 (n)
103 (n)
CT1
HNS-COVID-PK
Ashraf (RCT)
75%
0.25 [0.15-0.41]
no recov.
50 (n)
53 (n)
CT1
HNS-COVID-PK
Ashraf (RCT)
82%
0.18 [0.12-0.27]
viral+
107 (n)
103 (n)
CT1
HNS-COVID-PK
Ashraf (RCT)
77%
0.23 [0.14-0.38]
viral+
50 (n)
53 (n)
CT1
Al-Haidari (RCT)
96%
0.04 [0.00-0.70]
death
0/160
14/259
Al-Haidari (RCT)
93%
0.07 [0.02-0.30]
severe case
2/160
44/259
Aldwihi
24%
0.76 [0.54-1.03]
hosp.
85/345
152/393
Koshak (RCT)
75%
0.25 [0.03-2.22]
hosp.
1/91
4/92
Koshak (RCT)
43%
0.57 [0.42-0.78]
no recov.
34/91
60/92
Bencheqr.. (DB RCT)
69%
0.31 [0.01-7.19]
hosp.
0/29
1/23
Bencheqr.. (DB RCT)
9%
0.91 [0.48-1.72]
no improv.
28 (n)
23 (n)
Bencheqr.. (DB RCT)
35%
0.65 [0.29-1.43]
no improv.
28 (n)
23 (n)
Bencheqr.. (DB RCT)
43%
0.57 [0.22-1.43]
viral+
5/21
8/19
Said (RCT)
77%
0.23 [0.04-1.23]
recovery
30 (n)
30 (n)
Said (RCT)
89%
0.11 [0.02-0.58]
recovery
30 (n)
30 (n)
Said (RCT)
80%
0.20 [0.07-0.59]
no recov.
30 (n)
30 (n)
Said (RCT)
77%
0.23 [0.07-0.70]
no recov.
30 (n)
30 (n)
Said (RCT)
85%
0.15 [0.04-0.48]
no recov.
30 (n)
30 (n)
Said (RCT)
90%
0.10 [0.03-0.33]
no recov.
30 (n)
30 (n)
Said (RCT)
85%
0.15 [0.02-0.74]
no recov.
30 (n)
30 (n)
Said (RCT)
67%
0.33 [0.05-1.79]
no recov.
30 (n)
30 (n)
Said (RCT)
58%
0.42 [0.08-1.86]
no recov.
30 (n)
30 (n)
Said (RCT)
58%
0.42 [0.08-1.86]
no recov.
30 (n)
30 (n)
Said (RCT)
82%
0.18 [0.02-0.94]
no recov.
30 (n)
30 (n)
Said (RCT)
86%
0.14 [0.02-0.70]
no recov.
30 (n)
30 (n)
Said (RCT)
27%
0.73 [0.22-2.40]
no recov.
30 (n)
30 (n)
Said (RCT)
56%
0.44 [0.12-1.53]
no recov.
30 (n)
30 (n)
Said (RCT)
80%
0.20 [0.03-0.92]
no recov.
30 (n)
30 (n)
Said (RCT)
90%
0.10 [0.01-0.66]
no recov.
30 (n)
30 (n)
Said (RCT)
61%
0.39 [0.13-1.08]
viral+
30 (n)
30 (n)
Said (RCT)
85%
0.15 [0.04-0.51]
viral+
30 (n)
30 (n)
Said (RCT)
91%
0.09 [0.02-0.30]
viral+
30 (n)
30 (n)
Said (RCT)
87%
0.13 [0.03-0.45]
viral+
30 (n)
30 (n)
Karimi (RCT)
51%
0.49 [0.09-2.66]
death
2/192
4/189
CT1
Karimi (RCT)
61%
0.39 [0.08-2.00]
ICU
2/192
5/189
CT1
Karimi (RCT)
70%
0.30 [0.15-0.61]
hosp.
184 (n)
174 (n)
CT1
Karimi (RCT)
67%
0.33 [0.17-0.65]
no recov.
184 (n)
174 (n)
CT1
Karimi (RCT)
14%
0.86 [0.80-0.93]
no recov.
184 (n)
174 (n)
CT1
Setayesh (RCT)
-8%
1.08 [0.07-16.7]
death
1/38
1/41
CT1
Setayesh (RCT)
27%
0.73 [0.58-0.92]
oxygen time
38 (n)
41 (n)
CT1
Setayesh (RCT)
29%
0.71 [0.63-0.81]
hosp. time
38 (n)
41 (n)
CT1
Al-Haidari
62%
0.38 [0.31-0.46]
symp. case
68/188
180/188
Shehab
0%
1.00 [0.36-2.74]
severe case
4/39
22/214
Chandra (RCT)
49%
0.51 [0.16-1.59]
cases
4/52
8/53
CT1
Chandra (RCT)
87%
0.13 [0.02-0.84]
cases
1/51
8/53
CT1
Chandra (RCT)
74%
0.26 [0.06-1.17]
cases
2/51
8/53
CT1
Daneshfard (RCT)
34%
0.66 [0.49-0.89]
symp. case
37/89
53/84
CT1
Daneshfard (RCT)
97%
0.03 [0.00-0.19]
symp. case
1/89
35/84
CT1
Daneshfard (RCT)
66%
0.34 [0.11-1.04]
symp. case
4/89
11/84
CT1
Daneshfard (RCT)
62%
0.38 [0.12-1.16]
symp. case
4/89
10/84
CT1
Daneshfard (RCT)
26%
0.74 [0.50-1.09]
symp. case
29/89
37/84
CT1
Daneshfard (RCT)
-6%
1.06 [0.43-2.62]
symp. case
9/89
8/84
CT1
Daneshfard (RCT)
79%
0.21 [0.07-0.59]
symp. case
4/89
18/84
CT1
Daneshfard (RCT)
76%
0.24 [0.09-0.60]
symp. case
5/89
20/84
CT1
Daneshfard (RCT)
98%
0.02 [0.00-0.31]
symp. case
0/89
25/84
CT1
Nigella sativa COVID-19 outcomes
c19 early .org Sep 2023
1 CT: study uses combined treatment
Favors nigella sativa
Favors control
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit